Oct 2026· Spanish journal of psychiatry and mental health· 0 citations
Medicine
TL;DR
Significant associations were found between SD and polymorphisms in TNF-α, IL-2, IL-1β, IL-6, and IL-18, which support further research into immune-genetic mechanisms underlying antidepressant-associated sexual adverse effects.
Abstract
INTRODUCTION
Sexual dysfunction (SD) is a frequent adverse effect of antidepressants, affecting 20%-70% of patients. Although some studies have examined serotonergic, dopaminergic, and glutamatergic gene variants, results remain inconclusive. Given the role of inflammatory cytokines in antidepressant response, their genetic variants may also influence SD. The aim of this study is to investigate associations between inflammatory cytokine gene variants and antidepressant-induced SD.
Materials And Methods
A total of 99 Caucasian patients (51 women, 48 men) in remission or with mild depressive or anxiety symptoms and receiving stable SSRI or SNRI monotherapy were recruited. Participants completed a semistructured interview, clinical assessments, and the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX). DNA samples were genotyped for 61 single nucleotide polymorphisms (SNPs) in 9 cytokine-related genes (IL-1β, IL-2, IL-6, IL-6R, IL-8, IL-10, IL-18, TNF-α, IFN-γ). Analyses included linear and logistic regression, adjusting for age, sex, antidepressant type, dose, and treatment duration. Primary endpoints included the presence and severity of SD, with secondary outcomes focusing on associations between specific SNPs and SD subdomains.
Results
SD was reported by 78.8% of participants, and 57.6% experienced moderate-to-severe impairment; 60.8% did not report symptoms spontaneously. Significant associations were found between SD and polymorphisms in TNF-α, IL-2, IL-1β, IL-6, and IL-18. The TNF-α rs1799724-T allele was associated with a lower risk of SD, particularly delayed orgasm and absence of orgasm, whereas rs1799964-C was associated with an increased risk. The rs361525-A variant showed a protective effect against decreased libido. A TNF-α haplotype (rs1799724-T, rs1799964-T, rs1800629-G, rs3093664-A, rs361525-G) was inversely related to SD scores. IL-2 rs3136534-G increased SD risk, whereas rs1479923-A was protective. IL-1β haplotypes were associated with reduced sexual desire and dysfunction.
Conclusions
This study provides novel evidence linking inflammatory cytokine gene variants, especially TNF-α, to antidepressant-induced SD. These findings support further research into immune-genetic mechanisms underlying antidepressant-associated sexual adverse effects.
A sex-specific pathway linking NPY, metabolic dysfunction, and inflammation to cognitive decline in MDD is revealed, and the integrated biomarker panel offers superior diagnostic utility.
Qian-Fa Yuan, Mohammed A. M. Elhassan, Hong-He Zhang et al.· Biology of Sex Differences· 0 citations
While ACT and BATD improved clinical outcomes, their effects on immune-inflammatory biomarkers were not significant and underscore the need to further explore the interaction between psychological therapies, biological processes, and individual variability in treatment outcomes.
Adrián Pérez-Aranda, Carla Rodríguez-Freire, Juan P. Sanabria-Mazo et al.· The Clinical Journal of Pain· 1 citation
Background: Major depressive disorder (MDD) has frequently been associated with inflammation; however, the relationship between antidepressant-related side effects and inflammatory markers remains unclear. This study investigated the associations of antidepressant side effects with the neutrophil-to-lymphocyte ratio (N...
Ezgi Çankaya İnan, Mahmut Bulut, Betul Uyar· Journal of Clinical Medicine· 0 citations
Increased IL-6 and hsCRP showed a female-specific role in immunometabolic depression, with IL-6 emerging as a potential diagnostic biomarker, and the need to further investigate sex-specific immune biomarkers to inform sex-specific targeted treatments for this population is highlighted.
G. Lombardo, A. McLaughlin, E. Lambert et al.· International Journal of Neu...· 0 citations
OBJECTIVE
Mood disturbances-including depressed mood, irritability, anxiety, and mental exhaustion-are common during the menopause transition, affecting up to 68% of women. While menopausal hormone therapy (HT) is FDA-approved for vasomotor and genitourinary symptoms, its role in managing mood symptoms remains less wel...
Samantha Fairweather, Laurie Jeffers, Dana R. Gossett et al.· Menopause· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.